Vertex Pharmaceut…
USUSDVertex Pharmaceuticals Inc (US:VRTX) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het Bedrijf
- Website
- vrtx.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- Boston, United States
- Management
- Reshma Kewalramani
- Werknemers
- 6 400
- Opgericht
- 1989
- IPO
- 1991-07-24
- Uitstaande Aandelen
- 253.46 mln. per 2026-07-31
- Free Float
- 252.69 mln.
- Marktkapitalisatie
- 132.8 mld. USD
- Insiders
- 0.21%
- Institutionele Beleggers
- 97.94%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- ZJTK
- ISIN
- US92532F1003
- LEI
- 54930015RAQRRZ5ZGJ91
- P/E
- 30.8
- P/B
- 6.63
- FCF
- 3.80 mld. USD
- Schuld
- 0 USDnetto kaspositie
- Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
- Nettowinst
- NAV
Beschrijving
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Beurzen en Tickers
| Beurs | Ticker | Valuta | Prijs | Type |
|---|---|---|---|---|
| gewone aandelen | ||||
| US USA Stocks | VRTX primair | USD | 529.69 +1.66% | gewone aandelen |
| LSE London Stock Exchange | 0QZU IOB | USD | 525.23 +0.00% | gewone aandelen |
| MX Mexican Stock Exchange | VRTX secundair | MXN | 10 032 +0.00% | gewone aandelen |
| certificaat van aandelen | ||||
| SA B3 Sao Paulo | VRTX34 | BRL | 78.8 -8.22% | certificaat van aandelen |
Grootste Aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| Capital World Investors | 10.29% | 26.12 mln. | 2026-06-30 |
| Blackrock Inc. | 9.5% | 24.11 mln. | 2026-06-30 |
| Capital Research Global… | 7.68% | 19.49 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 16.58 mln. | 2026-06-30 |
| Growth Fund of America | 4.94% | 12.54 mln. | 2026-06-30 |
| State Street Corporation | 4.68% | 11.87 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.06 mln. | 2026-06-30 |
| Invesco Ltd. | 3.17% | 8.04 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 6.58 mln. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.57% | 6.52 mln. | 2026-06-30 |
| Investment Co of America | 2.47% | 6.27 mln. | 2026-06-30 |
| Geode Capital Management… | 2.37% | 6.02 mln. | 2026-06-30 |
| AMERICAN BALANCED FUND | 2.19% | 5.56 mln. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 5.46 mln. | 2026-08-31 |
| Vanguard Portfolio Manag… | 1.92% | 4.88 mln. | 2026-06-30 |
| Capital International In… | 1.85% | 4.7 mln. | 2026-06-30 |
| Amcap Fund | 1.83% | 4.65 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 3.38 mln. | 2026-08-31 |
| NEW PERSPECTIVE FUND | 1.33% | 3.37 mln. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 3.28 mln. | 2026-07-31 |
| ARBUCKLE STUART A (Chief… | ≈0.04% | 100 751 | 2025-05-13 |
| KEWALRAMANI RESHMA (Chie… | ≈0.04% | 98 278 | 2026-02-27 |
| SACHDEV AMIT (Officer) | ≈0.03% | 74 031 | 2026-07-21 |
| TATSIS OURANIA (Officer) | ≈0.02% | 53 572 | 2026-07-21 |
| WAGNER CHARLES F JR (Chi… | ≈0.02% | 48 786 | 2026-02-17 |
| SACHS BRUCE I (Director) | ≈0.02% | 45 000 | 2025-08-06 |
| LEIDEN JEFFREY M (Office… | ≈0.02% | 38 784 | 2026-02-17 |
| ALTSHULER DAVID (Officer… | ≈0.01% | 34 477 | 2026-01-22 |
| LIU JOY (Officer) | ≈0.01% | 19 131 | 2026-07-01 |
| ATKINSON EDWARD MORROW I… | ≈0.01% | 18 432 | 2026-02-25 |
Log in met Google